Suchergebnisse - "Tessa Niemeyer‐van der Kolk"

PubPharm (5)

1

Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.

in: Cancers | 2023

von Selinde S. Wind | Manon A. A. Jansen | Melanie Rijsbergen | +19

2

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial

in: International Journal of Molecular Sciences | 2023

von Jannik Rousel | Mahdi Saghari | Lisa Pagan | +12

3

Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial

in: Cancers | 2022

von Selinde S. Wind | Manon A. A. Jansen | Melanie Rijsbergen | +19

4

Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers

in: Clinical and Translational Science | 2020

von Tessa Niemeyer‐van der Kolk | Salma Assil | Thomas P. Buters | +9

5

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial

in: Clinical and Translational Science | 2020

von Tessa Niemeyer‐van der Kolk | Hein van derWall | Geretta K. Hogendoorn | +10

1
[1]